A Study to Compare Two Formulations of Xylometazoline/Dexpanthenol Nasal

Status Completed

Clinical Trial Summary

An observer-blind, multi-centre, randomized, parallel-group study to compare the efficacy and safety of two formulations of xylometazoline/dexpanthenol nasal spray for the treatment of nasal congestion caused by an acute upper respiratory tract infection in adults.

Clinical Trial Description

This observer-blind multi-center, randomized, parallel-group study in adults is designed to demonstrate non-inferiority between two formulations of xylometazoline/dexpanthenol nasal sprays in terms of efficacy and safety, when the products are used according to labeled instructions in a home based setting.

Subjects suffering from nasal congestion caused by acute Upper Respiratory Tract Infection (URTI) and seeking medical counselling, will after screening and baseline assessment of nasal congestion, be randomized, and perform additional baseline subjective assessments of nasal rhinorrhea (scores on categorical scales). The Investigator will perform subjective baseline assessments of crust formation and dryness, redness and edema of nasal mucosa (anterior rhinoscopy using nasal speculum or otoscope).

After the baseline assessments, the subjects will receive xylometazoline/dexpanthenol nasal spray or marketed reference nasal spray according to randomization.The first dose will be taken at the site under supervision. The study nurse will schedule visits for 24 hours, 72 hours and 120 hours after this first dose and the subjects will be released for home based treatment. At the 72-hour visit, the primary and secondary efficacy endpoints will be assessed by the subject and the Investigator, safety will be followed up and subjects will also evaluate the treatment in a global assessment. At the 24-hour visit and at the final visit, after a maximum of 5 full days (120 hours) of treatment, all secondary endpoints will be assessed and safety will be followed up. ;

Study Design

Related Conditions & MeSH terms

Nasal Congestion

Clinical Trial Details

NCT number	NCT03439436
Study type	Interventional
Source	Johnson & Johnson Consumer and Personal Products Worldwide
Contact
Status	Completed
Phase	Phase 3
Start date	February 26, 2018
Completion date	May 2, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00665977` - Effect of Heated Humidity With Thermosmart™ Compared to an Intranasal Steroid in Improving Compliance and Nasal Symptoms in Patients Using Continuous Positive Airway Pressure	Phase 3
Completed	`NCT05843071` - PMCF Study to Evaluate Performance and Safety of "NASAL SPRAYS " Used to Relieve Nasal Congestion and Dryness	N/A
Completed	`NCT00957996` - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza	Phase 3
Completed	`NCT00829634` - Steady State Kinetics of l-Methamphetamine and Validation of Sensitivity of Dose Estimation	N/A
Completed	`NCT00662337` - Bioequivalence Between Two Oral Formulations of Diphenhydramine Hydrochloride	Phase 1
Completed	`NCT05247333` - Implementation of a Minor Ailment Service in Community Pharmacy Practice	N/A
Recruiting	`NCT05244148` - Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects	N/A
Completed	`NCT05159271` - Efficacy and Safety of Azeol Nasal Spray Versus Placebo in the Treatment of Early Symptoms of Common Cold in Adults	N/A
Completed	`NCT02113449` - Market Potential of Carbon Dioxide Nasal Spray	Phase 2
Terminated	`NCT00958776` - A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza	Phase 3
Completed	`NCT00648973` - To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses	Phase 4
Completed	`NCT03399721` - Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis	N/A
Completed	`NCT01354418` - Bioequivalence of Single Dose Phenylephrine Extended Release Tablets and Phenylephrine HCl Immediate Release Tablets Dosed Every Four Hours (P08340)(COMPLETED)	Phase 1
Completed	`NCT04797936` - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19	Phase 4
Completed	`NCT03906968` - The Safety and Efficacy of a SinuSonic Intervention	N/A
Completed	`NCT02100605` - Study on Hypertonic Saline Nasal Spray	N/A
Recruiting	`NCT06323304` - Efficacy and Safety of Auricular Acupressure in Treating Allergic Rhinitis	N/A
Withdrawn	`NCT04790487` - Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis	Phase 2/Phase 3
Completed	`NCT01448057` - Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu	Phase 3
Completed	`NCT01129765` - Home Usability of a Nasal Lavage System in Children	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study to Compare Two Formulations of Xylometazoline/Dexpanthenol Nasal Spray for the Treatment of Nasal Congestion.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms